Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-04-25Clinical Trial Update: Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]
Phase 1 study of Descartes-11 in relapsed/refractory multiple myeloma was terminated, with results posted on 2025-04-25.
-
CLINICAL_TRIALS trial_result · 2025-04-25Clinical Trial Update: A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma [Phase 1]
Phase 1 study evaluating JNJ-54767414 (HuMax CD38) in combination with backbone therapies for multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: Improving Patient Experience: BMBA [NA]
The BMBA clinical trial sponsored by Thomas Jefferson University has completed, but no specific results are provided in the update.
-
CLINICAL_TRIALS trial_result · 2025-04-23Clinical Trial Update: China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma [Phase 3]
Phase 3 trial update evaluating the efficacy and safety of belantamab mafodotin with bortezomib and dexamethasone versus daratumumab with bo…
-
CLINICAL_TRIALS trial_result · 2025-04-22Clinical Trial Update: Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study [Phase 4]
A Phase 4 trial compares alternative pomalidomide dosing schedules (4 mg every other day vs 2 mg and 4 mg daily) in relapsed/refractory mult…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-04-20Clinical Trial Update: A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant [Phase 3]
Phase 3 trial comparing daratumumab plus lenalidomide versus lenalidomide alone as maintenance in newly diagnosed multiple myeloma patients …
-
CLINICAL_TRIALS trial_result · 2025-04-20Clinical Trial Update: A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant [Phase 3]
Phase 3 trial comparing daratumumab plus lenalidomide versus lenalidomide alone as maintenance in newly diagnosed, MRD-positive multiple mye…
-
CLINICAL_TRIALS trial_result · 2025-04-17Clinical Trial Update: Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma [Phase 1]
A Phase 1 study of CC-93269, a BCMA x CD3 T cell engaging antibody, in relapsed and refractory multiple myeloma has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) [Phase 2]
Phase 2 MATCH subprotocol study evaluating copanlisib as a targeted treatment for cancers with PTEN expression. The trial is currently activ…
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma [Phase 1]
A Phase 1 study evaluating OPB-31121 in relapsed or refractory Non-Hodgkin's Lymphoma and Multiple Myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2025-04-13Clinical Trial Update: A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma [Phase 3]
A Phase 3 study evaluating daratumumab in transplant-eligible patients with previously untreated multiple myeloma has completed. Results wer…
-
CLINICAL_TRIALS trial_result · 2025-04-10Clinical Trial Update: An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments [Phase 1]
Phase 1 open-label, dose-escalation study in Japanese patients with relapsed/refractory multiple myeloma who have failed prior anti-myeloma …
-
CLINICAL_TRIALS trial_result · 2025-04-08Clinical Trial Update: Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) [Phase 2]
Phase 2 MATCH subprotocol U update on defactinib (VS-6063) for cancers with NF2 genetic changes, with results posted and the trial listed as…
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 study of CID-103, an anti-CD38 antibody, in previously treated relapsed or refractory multiple myeloma has completed. The trial was …
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
An update on a Phase 1/2 study of belantamab mafodotin with cyclophosphamide and dexamethasone in relapsed/refractory multiple myeloma indic…
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma [Phase 2]
Phase 2 trial evaluating teclistamab plus autologous lymphocyte infusion for relapsed/refractory multiple myeloma. The study is currently no…
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
A clinical trial update indicates a study using Telo Genomics technology to detect and profile minimal residual disease in multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma [Phase 2]
Phase 2 trial evaluating cyclophosphamide as graft-versus-host disease prophylaxis after allogeneic stem cell transplantation in patients wi…
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Chemotherapy and G-CSF for Mobilization [Phase 2]
Phase 2 trial updating the use of chemotherapy with G-CSF for stem cell mobilization in multiple myeloma; the study has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
An update on the treatment of relapsed/refractory multiple myeloma with pomalidomide in clinical practice following completion of the trial.
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone [Phase 2]
Phase 2 clinical trial evaluating iberdomide in combination with low-dose cyclophosphamide and dexamethasone for multiple myeloma; the study…
-
CLINICAL_TRIALS trial_result · 2025-03-27Clinical Trial Update: Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation [Phase 1]
A Phase 1 trial evaluating the efficacy of a generic plerixafor in autologous hematopoietic stem cell transplantation has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma [Phase 1]
Phase 1 trial evaluating a conditioning regimen including bortezomib, total marrow irradiation, fludarabine phosphate, and melphalan for don…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma [NA]
The update notes the completion of a clinical trial studying plasma exchange for acute renal failure at the onset of multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
This clinical trial update reports the termination of a Phase 1 study evaluating the safety and tolerability of CC-92328 in participants wit…